|
|
Post by hammer on Dec 11, 2015 7:35:37 GMT -5
finance.yahoo.com/news/novo-nordisk-files-faster-acting-213509808.htmlThese are the developments that increase frustration levels. Although it is still injected its apparently given after the start of the meal. Filed with both FDA and EU. It appears that it will be available in EU before Afrezza will. The silver lining may be that now there may be a product in which we can compare to. Injected vs inhaled. Any one familiar with this product to know if it has any significant benefits to reduction of fasting blood glucose?
|
|
|
|
Post by reality on Dec 11, 2015 8:09:27 GMT -5
I saw this, felt compelled to sign up today and have no idea of the product, but do think it could help our cause as it could jolt Sanofi to wake up and smell the coffee. In hindsight I do believe Afrezza's other potential partner back in 2014 was Novo.
|
|
|
|
Post by hammer on Dec 11, 2015 8:25:41 GMT -5
NVO news is remarkable from a few points:
It confirms the move to finding better and faster acting prandial insulins. NVO clearly sees Afrezza as a threat!
I am sure SNY is well aware of the product we will have to see what their response will be. Will they pit Afrezza against the NVO product to show superiority? Do they have their own injectable faster acting ? Will they increase awareness and marketing push for AFrezza? Time will tell.
|
|
|
|
Post by peppy on Dec 11, 2015 8:26:35 GMT -5
finance.yahoo.com/news/novo-nordisk-files-faster-acting-213509808.htmlThese are the developments that increase frustration levels. Although it is still injected its apparently given after the start of the meal. Filed with both FDA and EU. It appears that it will be available in EU before Afrezza will. The silver lining may be that now there may be a product in which we can compare to. Injected vs inhaled. Any one familiar with this product to know if it has any significant benefits to reduction of fasting blood glucose? Novo Nordisk plans to deliver faster-acting insulin aspart in the prefilled delivery device, FlexTouch. A potential approval in both the U.S. and the EU will further strengthen Novo Nordisk’s diabetes portfolio. We note that the company has a strong presence in the Diabetes Care market and boasts a strong pipeline, with focus on therapeutic proteins within insulin. Victoza remains the growth engine at the company.
Another analogue. hexamer.
|
|
|
|
Post by compound26 on Dec 11, 2015 8:52:49 GMT -5
www.ncbi.nlm.nih.gov/pubmed/25846340Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.
Heise T1, Hövelmann U1, Brøndsted L2, Adrian CL2, Nosek L1, Haahr H2. Author information Abstract AIMS: To evaluate the pharmacokinetics and pharmacodynamics of faster-acting insulin aspart and insulin aspart in a randomized, single-centre, double-blind study. METHODS: Fifty-two patients with type 1 diabetes (mean age 40.3 years) received faster-acting insulin aspart, insulin aspart, or another faster aspart formulation (not selected for further development), each as a single 0.2 U/kg subcutaneous dose, under glucose-clamp conditions, in a three-way crossover design (3-12 days washout between dosing). RESULTS: Faster-acting insulin aspart had a faster onset of exposure compared with insulin aspart, shown by a 57% earlier onset of appearance [4.9 vs 11.2 min; ratio 0.43, 95% confidence interval (CI) 0.36; 0.51], a 35% earlier time to reach 50% maximum concentration (20.7 vs 31.6 min; ratio 0.65, 95% CI 0.59; 0.72) and a greater early exposure within 90 min after dosing. The greatest difference occurred during the first 15 min, when area under the serum insulin aspart curve was 4.5-fold greater with faster-acting insulin aspart than with insulin aspart. Both treatments had a similar time to maximum concentration, total exposure and maximum concentration. Faster-acting insulin aspart had a significantly greater glucose-lowering effect within 90 min after dosing [largest difference: area under the curve for the glucose infusion rate (AUC(GIR), 0-30 min) ratio 1.48, 95% CI 1.13; 2.02] and 17% earlier time to reach 50% maximum glucose infusion rate (38.3 vs 46.1 min; ratio 0.83, 95% CI 0.73; 0.94). The primary endpoint (AUC(GIR, 0-2 h)) was 10% greater for faster-acting insulin aspart, but did not reach statistical significance (ratio 1.10, 95% CI 1.00; 1.22). Both treatments had similar total and maximum glucose-lowering effects, indicating similar overall potency. CONCLUSIONS: Faster-acting insulin aspart was found to have earlier onset and higher early exposure than insulin aspart, and a greater early glucose-lowering effect, with similar potency.
|
|
|
|
Post by mssciguy on Dec 11, 2015 8:57:16 GMT -5
Paging Dr. Brandicourt. Don't drop the ball.
|
|
|
|
Post by jbe on Dec 11, 2015 9:42:58 GMT -5
Perhaps Sanofi should consider an injectable form of Afrezza, it would still be a faster acting and exiting insulin than Novo's new product.
Does Sanofi want to be competitive or not?
|
|
|
|
Post by dpca10 on Dec 11, 2015 10:03:35 GMT -5
The question is what's the offset time. Afrezza's curve eliminates the need to overly complicate the carb counting of the meal.
|
|
|
|
Post by factspls88 on Dec 11, 2015 10:06:41 GMT -5
Paging Dr. Brandicourt. Don't drop the ball. It's more like "Paging Dr. Brandicourt. Pick up the darn ball!" |
|
|
|
Post by compound26 on Dec 11, 2015 10:08:36 GMT -5
The question is what's the offset time. Afrezza's curve eliminates the need to overly complicate the carb counting of the meal. I would expect it will be similar to the existing RAAs. As the study indicates: both treatments had a similar time to maximum concentration. I would expect it will also take similar time to clear the faster-acting insulin aspart (as that of insulin aspart). www.ncbi.nlm.nih.gov/pubmed/25846340 |
|
|
|
Post by peppy on Dec 11, 2015 10:08:41 GMT -5
The question is what's the offset time. Afrezza's curve eliminates the need to overly complicate the carb counting of the meal. exactly. the label/ advertising, if afrezza could find a way to state, " Afrezza's curve eliminates the need to overly complicate the carb counting of the meal."
|
|
|
|
Post by compound26 on Dec 11, 2015 10:12:02 GMT -5
|
|
|
|
Post by bill on Dec 11, 2015 10:32:54 GMT -5
Perhaps Sanofi should consider an injectable form of Afrezza, it would still be a faster acting and exiting insulin than Novo's new product. Does Sanofi want to be competitive or not? Afrezza's uniqueness stems from its use of the monomer version of insulin. No one had found any way to stabilize the monomer version for subcutaneous injections in 90 years, but MNKD did it via the inhalation route. Bottom line is that an injectable form of Afrezza is a non-starter. |
|
|
|
Post by straightly on Dec 11, 2015 10:36:54 GMT -5
What is new with Nov ' s faster that makes it faster?
|
|
|
|
Post by peppy on Dec 11, 2015 10:48:05 GMT -5
What is new with Nov ' s faster that makes it faster? off the top of my head and I know nothing, what makes it faster, as near as I can figure out, a protein is changed in the sequence, and or ions are moved, charge is changed. what makes it new is it can be patented.
the words new and faster are part of a story. screencast.com/t/VQJhkSyQrr
|
|
